Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID NAPRAPAC 500 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID NAPRAPAC 500 COPACKAGED.
LANSOPRAZOLE vs PREVACID NAPRAPAC 500 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateTerminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."